Physcion inhibition of CYP2C9, 2D6 and 3A4 in human liver microsomes

References

• Adnan M, Rasul A, Hussain G, Shah MA, Sarfraz I, Nageen B, Riaz A, Khalid R, Asrar M, Selamoglu Z, et al. 2021. Physcion and physcion 8-O-β-d-glucopyranoside: natural anthraquinones with potential anticancer activities. Curr Drug Targets. 22(5):488–504. doi: 10.2174/1389450121999201013154542.
   PubMed Web of Science ®Google Scholar
• Almazroo OA, Miah MK, Venkataramanan R. 2017. Drug metabolism in the liver. Clin Liver Dis. 21(1):1–20. doi: 10.1016/j.cld.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Bahar MA, Setiawan D, Hak E, Wilffert B. 2017. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 18(7):701–739. doi: 10.2217/pgs-2017-0194.
   PubMed Web of Science ®Google Scholar
• Buters JT, Schiller CD, Chou RC. 1993. A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochem Pharmacol. 46(9):1577–1584. doi: 10.1016/0006-2952(93)90326-r.
   PubMed Web of Science ®Google Scholar
• Carrão DB, de Oliveira AR, Magalhães IR. 2018. Challenges of probe cocktail approach for human drug-drug interaction assays. Bioanalysis. 10(24):1969–1972. doi: 10.4155/bio-2018-0247.
   PubMed Web of Science ®Google Scholar
• Chen J, Stringer R, Shah B, Gu J, Zhang Y, Hackling M, Prince W, Woessner R. 2022. Drug-drug interaction studies to evaluate the effect of inhibition of UGT1A1 and CYP3A4 and induction of CYP3A4 on the pharmacokinetics of tropifexor in healthy subjects. Clin Pharmacol Drug Dev. 11(11):1253–1263. doi: 10.1002/cpdd.1140.
   PubMed Web of Science ®Google Scholar
• Ding M, Ma S, Liu D. 2003. Simultaneous determination of hydroxyanthraquinones in rhubarb and experimental animal bodies by high-performance liquid chromatography. Anal Sci. 19(8):1163–1165. doi: 10.2116/analsci.19.1163.
   PubMed Web of Science ®Google Scholar
• Dinger J, Meyer MR, Maurer HH. 2014. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett. 230(1):28–35. doi: 10.1016/j.toxlet.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Dong X, Wang L, Song G, Cai X, Wang W, Chen J, Wang G. 2021. Physcion protects rats against cerebral ischemia-reperfusion injury via inhibition of TLR4/NF-κB signaling pathway. Drug Des Devel Ther. 15:277–287. doi: 10.2147/DDDT.S267856.
   PubMed Web of Science ®Google Scholar
• Feng S, He X. 2013. Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity. Curr Drug Metab. 14(9):921–945. doi: 10.2174/138920021131400114.
   PubMed Web of Science ®Google Scholar
• Gao Y, Nan Z. 2022. Mechanistic insights into the use of rhubarb in diabetic kidney disease treatment using network pharmacology. Medicine. 101(1):e28465. doi: 10.1097/MD.0000000000028465.
   PubMed Web of Science ®Google Scholar
• Han M, Zhang X, Ye Z, Wang J, Kong Q, Hu X, Qian J, Cai J, Hu G. 2022. Effects of CYP2D6 genetic polymorphism and drug interaction on the metabolism of dacomitinib. Chem Res Toxicol. 35(2):265–274. doi: 10.1021/acs.chemrestox.1c00327.
   PubMed Web of Science ®Google Scholar
• Hohmann N, Haefeli WE, Mikus G. 2016. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 12(5):479–497. doi: 10.1517/17425255.2016.1163337.
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Z, Qi X, Gao N, Chang J, Yang M, Na S, Liu Y, Song R, Li L, et al. 2021. Rhubarb granule promotes diethylnitrosamine-induced liver tumorigenesis by activating the oxidative branch of pentose phosphate pathway via G6PD in rats. J Ethnopharmacol. 281:114479. doi: 10.1016/j.jep.2021.114479.
   PubMed Web of Science ®Google Scholar
• Huang Q, Lu G, Shen HM, Chung MC, Ong CN. 2007. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev. 27(5):609–630. doi: 10.1002/med.20094.
   PubMed Web of Science ®Google Scholar
• Ji XW, Lyu HJ, Zhou GH, Wu B, Zhu YY, Wu TH, Zhang F, Jin SN, Cho KW, Wen JF. 2021. Physcion, a tetra-substituted 9,10-anthraquinone, prevents homocysteine-induced endothelial dysfunction by activating Ca2+- and Akt-eNOS-NO signaling pathways. Phytomedicine. 81:153410. doi: 10.1016/j.phymed.2020.153410.
   PubMed Web of Science ®Google Scholar
• Kampe T, König A, Schroeder H, Hengstler JG, Niemeyer CM. 2014. Modular microfluidic system for emulation of human phase I/phase II metabolism. Anal Chem. 86(6):3068–3074. doi: 10.1021/ac404128k.
   PubMed Web of Science ®Google Scholar
• Kato M. 2008. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet. 23(2):87–94. doi: 10.2133/dmpk.23.87.
   PubMed Web of Science ®Google Scholar
• Kondža M, Bojić M, Tomić I, Maleš Ž, Rezić V, Ćavar I. 2021. Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules. 26(10):3018. doi: 10.3390/molecules26103018.
   PubMed Web of Science ®Google Scholar
• Kozakai K, Yamada Y, Oshikata M, Kawase T, Suzuki E, Haramaki Y, Taniguchi H. 2014. Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms. Drug Metab Pharmacokinet. 29(2):198–207. doi: 10.2133/dmpk.dmpk-13-rg-093.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho SJ, Kwon EY, Choi MS. 2019. Physcion reduces lipid accumulation and prevents the obesity in mice. Nutr Metab. 16(1):31. doi: 10.1186/s12986-019-0362-7.
   Google Scholar
• Li L, Wang L, Fan W, Jiang Y, Zhang C, Li J, Peng W, Wu C. 2020. The application of fermentation technology in traditional Chinese medicine: a review. Am J Chin Med. 48(4):899–921. doi: 10.1142/S0192415X20500433.
   PubMed Web of Science ®Google Scholar
• Lu TL, Su LL, Ji D, Gu W, Mao CQ. 2015. Interaction between CYP450 enzymes and metabolism of traditional Chinese medicine as well as enzyme activity assay. Zhongguo Zhong Yao Za Zhi. 40(18):3524–3529.
   PubMedGoogle Scholar
• Lynch T, Price A. 2007. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Ma J, Yang XY, Qiao L, Liang LQ, Chen MH. 2008. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy. J Dig Dis. 9(2):79–83. doi: 10.1111/j.1751-2980.2008.00326.x.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• Maréchal JD, Kemp CA, Roberts GC, Paine MJ, Wolf CR, Sutcliffe MJ. 2008. Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions. Br J Pharmacol. 153(1):S82–S89.
   PubMedGoogle Scholar
• Mattinen L, Kublbeck J, Rechardt O, Honkakoski P, Rautio J. 2014. Direct and rapid transcript analysis assay for CYP mRNA expression and inducibility in human primary hepatocytes. Drug Metab Lett. 8(2):77–87. doi: 10.2174/1872312808666140606101422.
   PubMedGoogle Scholar
• Mori K, Hashimoto H, Takatsu H, Tsuda-Tsukimoto M, Kume T. 2009. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an ­early stage of drug development. Xenobiotica. 39(6):415–422. doi: 10.1080/00498250902822204.
   PubMed Web of Science ®Google Scholar
• Qi F, Zhang W, Xue Y, Geng C, Jin Z, Li J, Guo Q, Huang X, Lu X. 2022. Microbial production of the plant-derived fungicide physcion. Metab Eng. 74:130–138. doi: 10.1016/j.ymben.2022.10.007.
   PubMed Web of Science ®Google Scholar
• Sun Y, He M, Sun Y, Wei J. 2021. 4-O-Galloylalbiflorin inhibits the activity of CYP3A, 2C9, and 2D in human liver microsomes. Xenobiotica. 51(8):871–876. doi: 10.1080/00498254.2021.1936688.
   PubMed Web of Science ®Google Scholar
• Tang JL, Liu BY, Ma KW. 2008. Traditional Chinese medicine. Lancet. 372(9654):1938–1940. doi: 10.1016/S0140-6736(08)61354-9.
   PubMed Web of Science ®Google Scholar
• Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. 2020. A review of the important role of CYP2D6 in pharmacogenomics. Genes. 11(11):1295. doi: 10.3390/genes11111295.
   PubMed Web of Science ®Google Scholar
• Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. 2020. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 108(2):191–200. doi: 10.1002/cpt.1830.
   PubMed Web of Science ®Google Scholar
• Tian D, Hu Z. 2014. CYP3A4-mediated pharmacokinetic interactions in cancer therapy. Curr Drug Metab. 15(8):808–817. doi: 10.2174/1389200216666150223152627.
   PubMed Web of Science ®Google Scholar
• Velizarova M, Abedinov P, Svinarov D, Nikolov V, Hristova J. 2022. Frequency distribution of CYP2C9 and VKORC1 mutations among Bulgarian patients and their importance for anticoagulant therapy. Clin Lab. 68(12):2527–2532. doi: 10.7754/Clin.Lab.2022.220213.
   Web of Science ®Google Scholar
• Wang K, Gao Q, Zhang T, Rao J, Ding L, Qiu F. 2020. Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. Drug Metab Rev. 52(2):235–257. doi: 10.1080/03602532.2020.1758714.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang X, Wang Z, Lv X, Yin H, Li W, Li W, Jiang L, Liu Y. 2022. Potential herb-drug interaction risk of thymoquinone and phenytoin. Chem Biol Interact. 353:109801. doi: 10.1016/j.cbi.2022.109801.
   PubMed Web of Science ®Google Scholar
• Xun L, Liu Y, Chu S, Yang S, Peng Y, Ren S, Wen B, Chen N. 2019. Physcion and physcion 8-O-β-glucopyranoside: a review of their pharmacology, toxicities and pharmacokinetics. Chem Biol Interact. 310:108722. doi: 10.1016/j.cbi.2019.06.035.
   PubMed Web of Science ®Google Scholar
• Yang C, Wang S, Guo X, Sun J, Liu L, Wu L. 2015. Simultaneous determination of seven anthraquinones in rat plasma by Ultra High Performance Liquid Chromatography-tandem Mass Spectrometry and pharmacokinetic study after oral administration of Semen Cassiae extract. J Ethnopharmacol. 169:305–313. doi: 10.1016/j.jep.2015.04.008.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zuo A, Deng Q, Liu S, Zhan T, Wang M, Xu H, Ma J, Zhao Y. 2020. Physcion protects against ethanol-induced liver injury by reprogramming of circadian clock. Front Pharmacol. 11:573074. doi: 10.3389/fphar.2020.573074.
   PubMed Web of Science ®Google Scholar
• Yildirim H, Tamer L, Sucu N, Atik U. 2008. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement. Med Princ Pract. 17(6):464–467. doi: 10.1159/000151568.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang X, Wang L, Badawy S, Liu Z, Xie C, Wang X, Tao Y. 2022. A new drug-drug interaction-tilmicosin reduces the metabolism of enrofloxacin through CYP3A4. Res Vet Sci. 148:33–41. doi: 10.1016/j.rvsc.2022.05.004.
   PubMed Web of Science ®Google Scholar
• Zhang N, Shon J, Kim MJ, Yu C, Zhang L, Huang SM, Lee L, Tran D, Li L. 2018. Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 11(3):251–260. doi: 10.1111/cts.12499.
   PubMed Web of Science ®Google Scholar
• Zhou J, Qian X, Zhou Y, Xiong S, Ji S, Wang Y, Zhao P. 2022. Human liver microsomes study on the inhibitory effect of plantainoside D on the activity of cytochrome P450 activity. BMC Complement Med Ther. 22(1):197. doi: 10.1186/s12906-022-03671-5.
   PubMedGoogle Scholar
• Zhou P. 2010. Traditional Chinese medicine. Comb Chem High Throughput Screen. 13(10):836–836. doi: 10.2174/138620710793360329.
   PubMed Web of Science ®Google Scholar
• Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 9(4):310–322. doi: 10.2174/138920008784220664.
   PubMed Web of Science ®Google Scholar
• Zhuang T, Gu X, Zhou N, Ding L, Yang L, Zhou M. 2020. Hepatoprotection and hepatotoxicity of Chinese herb rhubarb (Dahuang): how to properly control the "general (Jiang Jun)" in Chinese medical herb. Biomed Pharmacother. 127:110224. doi: 10.1016/j.biopha.2020.110224.
   PubMed Web of Science ®Google Scholar
• Zimmerman AD, Breckenridge CB, Yi KD, Sawhney Coder P, Wanders D, Judd RL, Foradori CD. 2018. Changes in hepatic phase I and phase II biotransformation enzyme expression and glutathione levels following atrazine exposure in female rats. Xenobiotica. 48(9):867–881. doi: 10.1080/00498254.2017.1374486.
   PubMed Web of Science ®Google Scholar